Cell-based regenerative medicine for renovascular disease

Research output: Contribution to journalReview articlepeer-review


Renal artery stenosis (RAS) elicits the development of hypertension and post-stenotic kidney damage, which may become irresponsive to restoration of arterial patency. Rather than mere losses of blood flow or oxygen supply, irreversible intrarenal microvascular rarefaction, tubular injury, and interstitial fibrosis are now attributed to intrinsic pathways activated within the kidney, focusing attention on the kidney parenchyma as a therapeutic target. Several regenerative approaches involving the delivery of reparative cells or products have achieved kidney repair in experimental models of RAS and the delivery of mesenchymal stem/stromal cells (MSCs) has already been translated to human subjects with RAS with promising results. The ongoing development of innovative approaches in kidney disease awaits application, validation, and acceptance as routine clinical treatment to avert kidney damage in RAS.

Original languageEnglish (US)
Pages (from-to)882-894
Number of pages13
JournalTrends in Molecular Medicine
Issue number9
StatePublished - Sep 2021


  • hypertension
  • mesenchymal stem/stromal cells
  • regeneration
  • renovascular disease

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology


Dive into the research topics of 'Cell-based regenerative medicine for renovascular disease'. Together they form a unique fingerprint.

Cite this